Compass Pathways (CMPS) Projected to Announce Earnings on Thursday

Compass Pathways (NASDAQ:CMPS) is anticipated to release its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Compass Pathways to announce earnings of ($0.3857) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. On average, analysts expect Compass Pathways to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Compass Pathways Stock Down 2.1%

CMPS stock opened at $11.93 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. The company’s 50 day simple moving average is $12.47 and its 200-day simple moving average is $8.96. Compass Pathways has a 12 month low of $3.92 and a 12 month high of $15.40. The firm has a market capitalization of $1.61 billion, a PE ratio of -3.79 and a beta of 2.47.

Analysts Set New Price Targets

A number of research firms recently issued reports on CMPS. Evercore raised Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 target price on the stock in a research note on Wednesday, July 8th. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Compass Pathways in a research report on Wednesday, July 8th. TD Cowen reissued a “buy” rating on shares of Compass Pathways in a report on Monday, June 1st. Wall Street Zen upgraded Compass Pathways from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, B. Riley Financial started coverage on Compass Pathways in a research note on Friday, April 24th. They set a “buy” rating and a $17.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.15.

Institutional Investors Weigh In On Compass Pathways

Several hedge funds have recently made changes to their positions in CMPS. RTW Investments LP grew its position in shares of Compass Pathways by 0.6% in the fourth quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock valued at $60,426,000 after purchasing an additional 50,000 shares during the period. Nantahala Capital Management LLC increased its stake in Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after purchasing an additional 1,350,698 shares during the last quarter. Millennium Management LLC increased its stake in Compass Pathways by 39.9% in the third quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after purchasing an additional 774,090 shares during the last quarter. Toronto Dominion Bank boosted its stake in Compass Pathways by 152.9% in the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock worth $17,447,000 after buying an additional 1,529,013 shares during the last quarter. Finally, ARK Investment Management LLC boosted its stake in Compass Pathways by 1.6% in the 4th quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock worth $14,876,000 after buying an additional 34,894 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.